Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Will Outfit Applied Precision s Cell Analyzer With Software

BELLEVUE, Wash., Oct. 27 (GenomeWeb News) - Cellomics will integrate an image-analysis toolkit with Applied Precision's automated cellular-imaging system, and both companies will sell the tool to the secondary screening, assay development, and academic markets, according to Applied Precision officials.

 

The exclusive OEM agreement may help Applied Precision gain a bigger foothold in the area of high-content analysis - a market segment it has only recently begun to explore - by equipping its instrument with a proven image-analysis package and providing the company with the marketing muscle of Cellomics' parent company Fisher Biosciences.

 

The deal was disclosed by Joe Victor, Applied Precision's senior vice president of life sciences, at IBC's Assays and Cellular Targets conference, held here this week.

The alliance provides Fisher's Cellomics business with what Applied Precision called a more affordable "entry-level" high-content scanner, which may help Cellomics expand the high-content screening market to smaller drug-discovery firms and academia, as well as drum up sales for its higher-end high-content screening instruments.

 

Under the terms of the agreement, which has yet to be publicly announced, Applied Precision will manufacture its CellWorx cellular-imaging platform for Cellomics, and Cellomics will equip Applied Precision with an instrument-specific image-analysis toolkit based on the software found in Cellomics' ArrayScan and KineticScan HCS readers.

 

Cellomics will then sell the product to the pharmaceutical markets in North America, Europe, and all areas in Asiaoutside of Singaporeand Taiwan, Victor told CBA News.

 

In addition, Applied Precision will then become the exclusive distributor of the combined product to academic researchers through its own sales channels in North America, Singapore, and Taiwan.

 

In both cases, Cellomics' intellectual property covering specific high-content screening methods will be included in the package, Victor said.

 

The complete version of this article appears in this week's Cell-Based Assay News, a GenomeWeb News sister publication.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.